ACCELERON PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 25 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-11-15: Reporting owner Smith Karen L.; Form 4; Security Option to Purchase Common Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-09-28: Reporting owner Kumar Ravindra; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-08-08: Reporting owner Kumar Ravindra; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-07-05: Reporting owner Kumar Ravindra; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-11-15 | Smith Karen L. Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $35.34 exercise price | 2017-11-15 | |
| 2017-09-28 | Kumar Ravindra Officer (SVP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,761 0 owned after | $5.28 exercise price | 2017-09-29 | |
| 2017-08-08 | Kumar Ravindra Officer (SVP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,065 3,624 owned after | $24.11 exercise price | 2017-08-09 | |
| 2017-07-05 | Kumar Ravindra Officer (SVP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −937 0 owned after | $7.12 exercise price | 2017-07-07 | |
| 2017-07-05 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,150 6,250 owned after | $5.28 exercise price | 2017-07-07 | |
| 2017-07-05 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,750 0 owned after | $7.12 exercise price | 2017-07-07 | |
| 2017-07-05 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 0 owned after | $7.12 exercise price | 2017-07-07 | |
| 2017-05-08 holding as of filing | Rovaldi Christopher Officer (SVP, Program Mgmt and Ops) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $30.17 exercise price | 2017-05-08 | ||
| 2017-05-08 holding as of filing | Rovaldi Christopher Officer (SVP, Program Mgmt and Ops) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $27.97 exercise price | 2017-05-08 | ||
| 2017-05-08 holding as of filing | Rovaldi Christopher Officer (SVP, Program Mgmt and Ops) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $41.20 exercise price | 2017-05-08 | ||
| 2017-05-08 holding as of filing | Rovaldi Christopher Officer (SVP, Program Mgmt and Ops) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $24.11 exercise price | 2017-05-08 | ||
| 2017-03-02 | Zakrzewski Joseph S Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | POPS RICHARD F Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | MCGUIRE TERRANCE Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | MCCOURT Thomas A Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,272 3,272 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Maniatis Tom Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Kearney Terrence C Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Nader Francois Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Kumar Ravindra Officer (SVP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,300 41,300 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Quisel John D Officer (SVP, Bus. Dev., GC & Secretary) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,300 46,300 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,300 41,300 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +47,300 47,300 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-03-02 | Ertel Steven D Officer (EVP & Chief Operating Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +47,300 47,300 owned after | $30.17 exercise price | 2017-03-14 | |
| 2017-01-03 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 6,251 owned after | $3.88 exercise price | 2017-01-04 |